Enzo Biochem Inc Financials
This page shows Enzo Biochem Inc (ENZB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Enzo Biochem’s visible mechanic is a cash-rich but self-funding-poor operating model: modest lab revenue has not been covering the cost base.
FY2023’s reported profit did not mark an operating turnaround: net income was$20.3M even as operating income was-$24.7M and operating cash flow was-$37.0M , while investing cash flow brought in$99.0M . That matters because FY2024 still shows the core business consuming cash—revenue stayed near$31.9M , but operating cash flow remained-$26.3M , so liquidity is being supported by earlier balance-sheet replenishment rather than current operations.
Margin improvement in FY2024 came more from cost reduction than scale. Revenue was essentially flat versus FY2023, yet gross margin improved to
The balance sheet is unusually light on debt for a company with recurring losses: cash of
Financial Health Signals
Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Enzo Biochem Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Enzo Biochem Inc has an operating margin of -38.8%, meaning the company retains $-39 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -79.6% the prior year.
Enzo Biochem Inc's revenue grew a modest 2.7% year-over-year to $31.9M. This slow but positive growth earns a score of 31/100.
Enzo Biochem Inc carries a low D/E ratio of 0.00, meaning only $0.00 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Enzo Biochem Inc's current ratio of 2.55 indicates adequate short-term liquidity, earning a score of 48/100. The company can meet its near-term obligations, though with limited headroom.
While Enzo Biochem Inc generated -$26.3M in operating cash flow, capex of $545K consumed most of it, leaving -$26.8M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Enzo Biochem Inc generates a -54.7% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from 27.3% the prior year.
Enzo Biochem Inc passes 3 of 9 financial strength tests. No profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Enzo Biochem Inc generates $1.01 in operating cash flow (-$26.3M OCF vs -$26.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Enzo Biochem Inc earns $-62.8 in operating income for every $1 of interest expense (-$12.4M vs $197K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Enzo Biochem Inc generated $31.9M in revenue in fiscal year 2024. This represents an increase of 2.7% from the prior year.
Enzo Biochem Inc's EBITDA was -$11.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 49.7% from the prior year.
Enzo Biochem Inc reported -$26.1M in net income in fiscal year 2024. This represents a decrease of 228.5% from the prior year.
Enzo Biochem Inc earned $-0.51 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 224.4% from the prior year.
Cash & Balance Sheet
Enzo Biochem Inc generated -$26.8M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 32.5% from the prior year.
Enzo Biochem Inc held $47.7M in cash against $155K in long-term debt as of fiscal year 2024.
Enzo Biochem Inc had 52M shares outstanding in fiscal year 2024. This represents an increase of 3.5% from the prior year.
Margins & Returns
Enzo Biochem Inc's gross margin was 45.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 3.4 percentage points from the prior year.
Enzo Biochem Inc's operating margin was -38.8% in fiscal year 2024, reflecting core business profitability. This is up 40.9 percentage points from the prior year.
Enzo Biochem Inc's net profit margin was -81.7% in fiscal year 2024, showing the share of revenue converted to profit. This is down 147.0 percentage points from the prior year.
Enzo Biochem Inc's ROE was -54.7% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 82.0 percentage points from the prior year.
Capital Allocation
Enzo Biochem Inc invested $2.6M in research and development in fiscal year 2024. This represents a decrease of 32.3% from the prior year.
Enzo Biochem Inc invested $545K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 80.3% from the prior year.
ENZB Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M-12.7% | $7.3M+18.0% | $6.2M-17.4% | $7.5M-6.2% | $8.0M-6.2% | $8.6M+9.6% | $7.8M-12.9% | $9.0M |
| Cost of Revenue | $3.8M | N/A | $3.7M-14.5% | $4.3M+0.4% | $4.3M-0.9% | $4.3M-0.5% | $4.4M+4.0% | $4.2M |
| Gross Profit | $2.6M | N/A | $2.5M-21.4% | $3.2M-13.7% | $3.7M-11.6% | $4.2M+22.3% | $3.5M-27.6% | $4.8M |
| R&D Expenses | $504K+5.2% | $479K-14.8% | $562K-7.6% | $608K+0.5% | $605K+4.3% | $580K-31.7% | $849K-29.0% | $1.2M |
| SG&A Expenses | $4.9M+7.6% | $4.6M-6.6% | $4.9M-5.6% | $5.2M+15.4% | $4.5M-11.6% | $5.1M-27.7% | $7.0M-30.8% | $10.1M |
| Operating Income | -$3.4M-111.5% | -$1.6M+55.8% | -$3.6M-36.1% | -$2.7M-30.2% | -$2.0M+6.5% | -$2.2M+60.1% | -$5.5M+24.0% | -$7.2M |
| Interest Expense | N/A | N/A | N/A | $2.8M+484.7% | -$726K+18.7% | -$893K+8.6% | -$977K-180.0% | $1.2M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$2.8M-81.8% | -$1.5M+54.5% | -$3.4M+74.8% | -$13.4M-343.1% | -$3.0M+1.3% | -$3.1M+53.7% | -$6.6M-111.5% | $57.4M |
| EPS (Diluted) | $-0.05-66.7% | $-0.03+57.1% | $-0.07 | N/A | $-0.060.0% | $-0.06+53.8% | $-0.13 | N/A |
ENZB Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $63.5M-5.9% | $67.5M-10.3% | $75.3M-12.2% | $85.8M-8.2% | $93.5M-5.7% | $99.1M-6.8% | $106.3M-12.8% | $121.9M |
| Current Assets | $48.3M-7.5% | $52.2M-12.5% | $59.7M-14.8% | $70.0M-7.5% | $75.7M-6.4% | $80.9M-8.1% | $88.0M-10.6% | $98.5M |
| Cash & Equivalents | $36.7M-8.9% | $40.3M-15.6% | $47.7M-8.9% | $52.4M-8.4% | $57.2M-5.1% | $60.2M-13.0% | $69.2M-16.0% | $82.4M |
| Inventory | $5.7M-4.6% | $6.0M-6.3% | $6.4M-6.5% | $6.8M-6.7% | $7.3M-6.1% | $7.8M+2.7% | $7.6M-4.3% | $7.9M |
| Accounts Receivable | $4.3M+1.5% | $4.2M+10.5% | $3.8M-3.7% | $4.0M+1.3% | $3.9M-23.1% | $5.1M+22.4% | $4.2M-13.0% | $4.8M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $20.1M-3.7% | $20.9M-24.4% | $27.6M-6.8% | $29.7M+21.3% | $24.4M-13.7% | $28.3M-11.6% | $32.0M-26.2% | $43.4M |
| Current Liabilities | $17.0M-1.0% | $17.2M-26.6% | $23.4M-5.6% | $24.8M+14.5% | $21.7M-14.3% | $25.3M-12.3% | $28.8M-27.9% | $40.0M |
| Long-Term Debt | $129K-11.6% | $146K-5.8% | $155K-18.0% | $189K+5.0% | $180K-23.1% | $234K+6.8% | $219K-18.6% | $269K |
| Total Equity | $43.4M-6.9% | $46.6M-2.2% | $47.7M-15.1% | $56.1M-18.7% | $69.0M-2.5% | $70.8M-4.7% | $74.3M-5.3% | $78.5M |
| Retained Earnings | -$302.1M-0.9% | -$299.3M-0.5% | -$297.8M-1.1% | -$294.4M-4.8% | -$281.0M-1.1% | -$278.0M-1.1% | -$275.0M-2.5% | -$268.4M |
ENZB Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.2M-58.9% | -$2.0M+77.5% | -$9.0M-728.6% | -$1.1M+62.1% | -$2.9M+68.0% | -$8.9M+33.2% | -$13.4M+21.5% | -$17.0M |
| Capital Expenditures | $386K+451.4% | $70K-84.4% | $448K+264.2% | $123K-14.0% | $143K+472.0% | $25K-90.2% | $254K-55.7% | $573K |
| Free Cash Flow | -$3.6M-72.0% | -$2.1M+77.8% | -$9.4M-681.3% | -$1.2M+59.8% | -$3.0M+66.5% | -$9.0M+34.2% | -$13.6M+22.6% | -$17.6M |
| Investing Cash Flow | -$386K-451.4% | -$70K-101.5% | $4.6M+3800.8% | -$123K+14.0% | -$143K-472.0% | -$25K+90.2% | -$254K-100.3% | $101.2M |
| Financing Cash Flow | -$42K+99.2% | -$5.3M-2562.0% | -$200K+94.5% | -$3.6M-8102.3% | -$44K-100.0% | -$22K+95.8% | -$518K+87.8% | -$4.2M |
| Dividends Paid | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ENZB Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 41.3% | N/A | 40.8%-2.0pp | 42.8%-3.7pp | 46.5%-2.9pp | 49.4%+5.1pp | 44.3%-9.0pp | 53.3% |
| Operating Margin | -52.9%-31.1pp | -21.8%+36.5pp | -58.3%-22.9pp | -35.4%-9.9pp | -25.5%+0.1pp | -25.6%+44.6pp | -70.2%+10.3pp | -80.5% |
| Net Margin | -43.6%-22.7pp | -20.9%+33.4pp | -54.3%+123.5pp | -177.8%-140.2pp | -37.6%-1.9pp | -35.8%+49.0pp | -84.8%-725.8pp | 641.0% |
| Return on Equity | -6.4%-3.1pp | -3.3%+3.8pp | -7.1%+16.8pp | -23.8%-19.5pp | -4.4%-0.1pp | -4.3%+4.6pp | -8.9%-82.1pp | 73.2% |
| Return on Assets | -4.4%-2.1pp | -2.3%+2.2pp | -4.5%+11.1pp | -15.6%-12.4pp | -3.2%-0.1pp | -3.1%+3.1pp | -6.2%-53.3pp | 47.1% |
| Current Ratio | 2.84-0.2 | 3.04+0.5 | 2.55-0.3 | 2.82-0.7 | 3.50+0.3 | 3.20+0.1 | 3.05+0.6 | 2.46 |
| Debt-to-Equity | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.000.0 | 0.00 |
| FCF Margin | -56.3%-27.8pp | -28.6%+123.3pp | -151.9%-135.9pp | -16.1%+21.4pp | -37.5%+67.3pp | -104.8%+69.8pp | -174.6%+21.9pp | -196.5% |
Similar Companies
Frequently Asked Questions
What is Enzo Biochem Inc's annual revenue?
Enzo Biochem Inc (ENZB) reported $31.9M in total revenue for fiscal year 2024. This represents a 2.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Enzo Biochem Inc's revenue growing?
Enzo Biochem Inc (ENZB) revenue grew by 2.7% year-over-year, from $31.1M to $31.9M in fiscal year 2024.
Is Enzo Biochem Inc profitable?
No, Enzo Biochem Inc (ENZB) reported a net income of -$26.1M in fiscal year 2024, with a net profit margin of -81.7%.
What is Enzo Biochem Inc's EBITDA?
Enzo Biochem Inc (ENZB) had EBITDA of -$11.1M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Enzo Biochem Inc have?
As of fiscal year 2024, Enzo Biochem Inc (ENZB) had $47.7M in cash and equivalents against $155K in long-term debt.
What is Enzo Biochem Inc's gross margin?
Enzo Biochem Inc (ENZB) had a gross margin of 45.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Enzo Biochem Inc's operating margin?
Enzo Biochem Inc (ENZB) had an operating margin of -38.8% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Enzo Biochem Inc's net profit margin?
Enzo Biochem Inc (ENZB) had a net profit margin of -81.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Enzo Biochem Inc's return on equity (ROE)?
Enzo Biochem Inc (ENZB) has a return on equity of -54.7% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Enzo Biochem Inc's free cash flow?
Enzo Biochem Inc (ENZB) generated -$26.8M in free cash flow during fiscal year 2024. This represents a 32.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Enzo Biochem Inc's operating cash flow?
Enzo Biochem Inc (ENZB) generated -$26.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Enzo Biochem Inc's total assets?
Enzo Biochem Inc (ENZB) had $75.3M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Enzo Biochem Inc's capital expenditures?
Enzo Biochem Inc (ENZB) invested $545K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Enzo Biochem Inc spend on research and development?
Enzo Biochem Inc (ENZB) invested $2.6M in research and development during fiscal year 2024.
What is Enzo Biochem Inc's current ratio?
Enzo Biochem Inc (ENZB) had a current ratio of 2.55 as of fiscal year 2024, which is generally considered healthy.
What is Enzo Biochem Inc's debt-to-equity ratio?
Enzo Biochem Inc (ENZB) had a debt-to-equity ratio of 0.00 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Enzo Biochem Inc's return on assets (ROA)?
Enzo Biochem Inc (ENZB) had a return on assets of -34.6% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Enzo Biochem Inc's cash runway?
Based on fiscal year 2024 data, Enzo Biochem Inc (ENZB) had $47.7M in cash against an annual operating cash burn of $26.3M. This gives an estimated cash runway of approximately 22 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Enzo Biochem Inc's Piotroski F-Score?
Enzo Biochem Inc (ENZB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Enzo Biochem Inc's earnings high quality?
Enzo Biochem Inc (ENZB) has an earnings quality ratio of 1.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Enzo Biochem Inc cover its interest payments?
Enzo Biochem Inc (ENZB) has an interest coverage ratio of -62.8x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Enzo Biochem Inc?
Enzo Biochem Inc (ENZB) scores 30 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.